机构：[1]Department of Ophthalmology, People's Hospital, Peking University, Beijing 100044, China.[2]Eye Diseases and Optometry Institute, College of Optometry, Peking University Health Science Center, Beijing 100044, China.[3]Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China.
To evaluate the two-year outcomes of patients treated for diabetic macular edema (DME) with intravitreal Conbercept (IVC).The clinical data of 30 DME patients (36 eyes) were retrospectively reviewed. The patients were treated with IVC for 3mo. Additional IVC was given at subsequent monthly visits, if needed (3+PRN). The patients were followed up for 24mo.The best-corrected visual acuity (BCVA) at 24mo significantly increased (66.7±15.3 letters) in comparison with the baseline (54.4±15.4 letters, P<0.0001). The mean improvement in BCVA was 11.0±2.9 letters. At 24mo, 44.1% of the eyes surveyed gained ≥15 letters, 52.9% of the eyes gained ≥10 letters, and 70.6% of the eyes gained ≥5 letters. No vision loss was noted in 96.8% of the eyes, and 5.9% of the eyes lost ≥5 letters, but ≤10 letters. The central retinal thickness (CRT) at 24mo was significantly reduced (277.1±122.9 µm) in comparison with the baseline (510.9±186.1 µm, P<0.0001). At 24mo, 43.3% of the patients had a CRT ≤250 µm. The mean number of injections over 24mo was 10.6±2.0. No severe eye or systemic adverse events related to either the drug or injection were noted.IVC is safe and effective for the treatment of DME.International Journal of Ophthalmology Press.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类|3 区医学
小类|3 区眼科学
最新[2025]版：
大类|4 区医学
小类|3 区眼科学
第一作者：
第一作者机构：[1]Department of Ophthalmology, People's Hospital, Peking University, Beijing 100044, China.[2]Eye Diseases and Optometry Institute, College of Optometry, Peking University Health Science Center, Beijing 100044, China.[3]Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Ophthalmology, People's Hospital, Peking University, Beijing 100044, China.[2]Eye Diseases and Optometry Institute, College of Optometry, Peking University Health Science Center, Beijing 100044, China.[3]Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China.[*1]Department of Ophthalmology, People's Hospital, Peking University, Bejjing 100044, China.
推荐引用方式(GB/T 7714)：
Cheng Yong,Yuan Li,Zhao Ming-Wei,et al.Real-world outcomes of two-year Conbercept therapy for diabetic macular edema.[J].International Journal of Ophthalmology.2021,14(3):416-422.doi:10.18240/ijo.2021.03.14.
APA：
Cheng Yong,Yuan Li,Zhao Ming-Wei&Qian Tong.(2021).Real-world outcomes of two-year Conbercept therapy for diabetic macular edema..International Journal of Ophthalmology,14,(3)
MLA：
Cheng Yong,et al."Real-world outcomes of two-year Conbercept therapy for diabetic macular edema.".International Journal of Ophthalmology 14..3(2021):416-422
